Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 15.2% – What’s Next?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock price was up 15.2% during trading on Thursday . The stock traded as high as $21.50 and last traded at $22.4270. 2,884,457 shares traded hands during trading, a decline of 5% from the average daily volume of 3,051,465 shares. The stock had previously closed at $19.46.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SRPT. Zacks Research raised Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research report on Thursday, July 9th. Wall Street Zen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Finally, Piper Sandler lowered their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research report on Thursday, July 9th. Nine investment analysts have rated the stock with a Buy rating, six have given a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $25.06.

Sarepta Therapeutics Stock Up 15.2%

The business has a fifty day moving average of $17.58 and a 200 day moving average of $18.28. The company has a market capitalization of $2.37 billion, a PE ratio of -7.66, a PEG ratio of 0.28 and a beta of 0.23. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.22 by $0.42. The company had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm’s revenue was down 34.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.02 EPS. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SRPT. PNC Financial Services Group Inc. boosted its holdings in shares of Sarepta Therapeutics by 7.8% in the first quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 636 shares during the period. Thrivent Financial for Lutherans increased its stake in Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock valued at $396,000 after buying an additional 744 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Sarepta Therapeutics by 1.8% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock worth $829,000 after buying an additional 758 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of Sarepta Therapeutics by 82.5% in the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 851 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its holdings in shares of Sarepta Therapeutics by 3.1% in the first quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company’s stock valued at $626,000 after acquiring an additional 875 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.